Skip to main content
. Author manuscript; available in PMC: 2012 Feb 8.
Published in final edited form as: Anticancer Agents Med Chem. 2010 Dec;10(10):722–734. doi: 10.2174/187152010794728657

Table 4.

FAK Inhibitors

Inhibitor Name Chemical Name Structure
PF 573,228 (PF-228) 6-(4-(3-(methylsulfonyl)
benzylamino)-5-
(trifluoromethyl)pyrimidin-
2-ylamino)-3, 4-dihydro
quinolin-2(1H)-one		 graphic file with name nihms348296t1.jpg Pfizer
PF562, 271-26 (PF-271) N-Methyl-N-(3-
{[2-(2-oxo-2,3-dihydro-1H-indol-
5-ylamino)-5-trifluoromethyl-
pyrimidin-4-ylamino]-methyl}-
pyridin-2-yl)-methanesulfonamide		 graphic file with name nihms348296t2.jpg Pfizer
NVP-226 (2-[5-Chloro-2-[2-methoxy-4-
(4-morpholinyl)phenylamino]
pyrimidin-4-ylamino]-N-
methylbenzamide		 graphic file with name nihms348296t3.jpg Novartis
Y15* 1,2,4,5-Benzenetetraamine
tetrahydrochloride		 graphic file with name nihms348296t4.jpg
· 4HH2CI
PND-1186** 2,4-diamino-pyridine-based;
X=bond or
(C1-C3)alkyl comprising
0–1 heteroatom selected
from the group consisting
of N, O, S(O) and S(O)2,
the (C1-C3)alkyl is
substituted with 0–1 hydroxy,
halo, (C1-C3)alkoxy,
(C1-C3)alkylamino or
(C1-C3)2dialkylamino groups.
R1 and R2 are 5–12 membered
Mono-, bi- or polycyclic,
aromatic or partially aromatic rings.
R3 is a trifluoromethyl,
halo, nitro or cyano; salt, tautomer,
solvate, hydrate, or aprodrug.		 graphic file with name nihms348296t5.jpg
*

Reported by Golubovskaya et al., J. Med. Chem, V 51, p7405–7416, 2008, ref. in (15).

**

Reported by Tanjoni et al., Cancer Biol. Ther., 2010, V 15, 2010, ref in (17).